Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Biosimilars Game On: Filing Chases AbbVie's Humira

This article was originally published in Scrip

Executive Summary

After being the company whose products have been in hot pursuit by makers of biosimilars, Amgen Inc. is seeking to market one of its own, ABP 501, a biosimilar version of AbbVie Inc.'s Humira (adalimumab) – aiming to take a bite out of the nearly $13bn in annual sales the latter firm brings in for its tumor necrosis factor (TNF) blocker.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts